Why Aclarion Presenting At The "State of Spine Surgery Think Tank" Could Push Its Stock To Its $481/sh Analyst's Price Target
Aclarion Presenting at the State of Spine Surgery
Think Tank is a very big deal for Aclarion.
The State of Spine Surgery Think Tank is one of the most prestigious and intimate gatherings in the spine care world. It’s not your typical trade show—it’s a high-level forum where top surgeons, medical device executives, VCs, and strategic investors engage in candid, forward-looking discussions.
Aclarion’s participation is especially notable because:
-
Dr. Kris Radcliff, a respected spine surgeon, is presenting their NOCISCAN platform, which uses MR spectroscopy and AI to pinpoint discogenic pain.
Dr. Radcliff Is A Major KOL
-
Dr. Radcliff has actively integrated NOCISCAN into his spine surgery practice, using it to identify discogenic pain in patients with chronic low back pain. This means he’s not just endorsing Aclarion's game-changing tech—he’s applying it in real-world cases to guide surgical decisions,
-
See the graphic below why Dr. Radcliff is sold on Aclarion's Nociscan as revolutionary:
The presentation is part of the Innovation and Investment Summit, a pre-conference event that specifically targets emerging technologies and investment opportunities.
Aclarion is positioning NOCISCAN as a new gold standard for diagnosing chronic low back pain—an area affecting over 266 million people globally.
The U.S. Lower Back Pain & Spine Surgery Market was $134.5 Billion in 2024, with a CAGR of 4.25%.
This kind of exposure—especially with real-world clinical integration being showcased—can open doors to strategic partnerships, clinical adoption, and investor interest.
It’s not just a speaking slot; it’s a seat at the table
with the people who shape the future of spine care.
The U.S. Lower Back Pain & Spine Surgery Market was $134.5 Billion in 2024, with a CAGR of 4.25%.
This kind of exposure—especially with real-world clinical integration being showcased—can open doors to strategic partnerships, clinical adoption, and investor interest.
It’s not just a speaking slot-- it’s a seat at the table
with the people who shape the future of spine care.
Our top pick shown on our YT Video to "Buy Out" Aclarion is also attending the Conference:
Medtronic (MDT) Just a coincidence? Yeah, right.
It's a spine conference folks, MDT serves all heath areas,
so WHY a major spine conference? Here's why:
Aclarion's CEO Brent Ness held senior leadership positions
at Medtronic, there's massive sympatico here.
MDT is looking to expand in this MR Spectroscopy area, so is Radnet. (RDNT) This conference is exactly what's needed to kickstart the "Buy Out Bidding War" leaked on Twitter, and spread all over Social Media platforms like Reddit's WallStreetBets, Stocktwits, Investor Hub, Stockscan, and more...that day is coming very soon.
​
This is why the $481 PT exists. Analysts understand how
VALUABLE Nociscan is. When a bidding was starts on this stock with a tiny 582K float, --forget the moon--
it will skyrocket to the stars...
​
Other Pubcos attending are:
Globus Medical (GMED) – Known for active participation in spine innovation forums.
Orthofix (OFIX) – Often involved in strategic discussions around spine hardware and biologics.
Alphatec Spine (ATEC) – A regular at spine-focused summits and innovation showcases.
​
All of these may join the bidding war as well.
Stay tuned, it's about to get spine tingling!
